BOTHELL, Wash., April 18 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC Bulletin Board: HXBM) today announced that Timothy Falla, Ph.D, Chief
Scientific Officer, will present an update on the company's new generation
of small molecule peptide (lipohexapeptide) technology at the BIO
International Convention. The convention will take place at the Boston
Convention & Exhibition Center in Boston, MA from May 6th through 9th. Dr.
Falla's presentation is scheduled for Wednesday, May 9th, Room D at 10:00
am.
Dr. Falla's presentation will discuss the company's research on the
potential of lipohexapeptides as broad spectrum anti-infectives in the
prevention of wound infections caused by multiple-resistant hard to treat
pathogens such as Pseudomonas aeruginosa in burns, Staphylococcus aureus in
surgical wounds and Acinetobacter baumannii in trauma wounds. The company's
lipohexapeptides are designed specifically to overcome the disadvantages
that have hampered the industry's previous attempts to develop therapeutic
antimicrobial peptides. These 'new generation' peptides are excellent drug
candidates due to their low toxicity, attractive cost of goods profile, and
evidence of efficacy in both bacterial and fungal infection models.
Helix BioMedix's peptides are also currently bringing value-added
performance benefits to the cosmeceutical and personal care markets in the
areas of anti-acne and anti-aging skin care. The company believes that an
increasing number of industry leaders and skin care clinicians are
identifying peptides as the next generation of cosmetic skin care
technology and the company's proprietary peptides are being incorporated
into a growing number of products through various licensing agreements.
Helix BioMedix will be participating in the BIO Business Forum
Partnering Program. In 2007, Helix BioMedix has plans to accelerate its
entry into the arena of pharmaceutical topical anti-infectives with a focus
on the large anti-infective dermatology market, including indications such
as acne and dermatitis. The company also hopes to increase the number of
peptide-enhanced personal care products that contain Helix BioMedix
peptides in the next several years.
The Biotechnology Industry Organization (BIO), founded in 1993, is a
nonprofit association that represents more than 1,100 biotechnology
companies, state and international affiliates, and related organizations.
BIO is widely known for the BIO International Convention, a four-day annual
biotechnology showcase that draws about 20,000 attendees. The convention
serves to educate the public and policymakers about biotechnology, while
fostering partnering meetings and other business development activities
that keep the industry growing.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company with a vast library
of diverse bioactive peptides and patents covering six distinct classes and
hundreds of thousands of peptide sequences. The company's mission is to
enrich clinical practice and the patient and consumer experience by
expanding opportunities to tap the health, beauty and safety benefits of
advanced bioactive small molecule technology. Its vision is to be
recognized as the world leader in the identification, qualification and
commercialization of natural and synthetic peptide technology.
The company's core competencies include peptide design, synthesis and
characterization together with assay development, screening, tissue culture
and microbiology. These areas of expertise are leveraged through
relationships with contract research organizations and peptide
manufacturers for the capability to take a program from theoretical concept
to a validated and qualified skin care active with respect to both efficacy
and safety. Applications for Helix BioMedix peptides include anti-aging
cosmeceutical skin care, acne treatment and other topical anti-infective
pharmaceuticals and wound healing. In addition to our primary focus on
peptides for dermatological applications, the company's peptide library
also holds promise for advancements in other therapeutic and industrial
areas such as oral care, biocides and animal health.
More information about the company and its proprietary peptides may be
found on the company's website at http://www.helixbiomedix.com .
Important Notice
This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include statements regarding activities, events or developments that the
company expects, believes or anticipates may occur in the future, including
statements related to our potential growth, product development and
commercialization and revenue. A number of factors could cause actual
results to differ from those indicated in the forward-looking statements,
including the company's ability to successfully raise additional capital,
enter into revenue generating license agreements, continue its research and
development efforts, including pre-clinical and clinical studies, and
general economic conditions. Additional assumptions, risks and
uncertainties are described in detail in our reports and other filings with
the Securities and Exchange Commission. Such filings are available on our
website or at http://www.sec.gov. Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual results
or developments may differ materially from those set forth in the
forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact:
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com/
CONTACT:
investors, Alison Ziegler of Cameron
Associates, +1-212-554-5469, alison@cameronassoc.com, for Helix
BioMedix, Inc.
|
